Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAdOx1 MERS vaccine in healthy volunteers
NCT03399578Phase 1Terminated
- Sponsor
- University of Oxford
- Start
- Mar 2018
- Primary completion
- Sep 2021
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ChAdOx1 MERS in Middle East respiratory syndrome (MERS) (5 arms), sponsored by University of Oxford. Primary endpoint: Occurrence of solicited and unsolicited local and systemic adverse events at 28 days. Started Mar 2018; status: terminated.
02
Drugs
ChAdOx1 MERS
03
Conditions
Middle East respiratory syndrome (MERS)
Beyond the preview
Go deeper on NCT03399578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399578.